LVivo IQS vs Tempus ECG-AF
AI Verdict
Choose LVivo IQS if…
Choose LVivo IQS if your primary need is to enhance the efficiency and accuracy of ultrasound image analysis, particularly for real-time cardiac function assessment. This tool is ideal for clinicians seeking AI-powered feedback during scans or automated post-scan analysis of LV/RV function to reduce variability and improve diagnostic confidence.
View LVivo IQS →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your goal is to proactively identify older patients at increased risk of developing new-onset atrial fibrillation within the next year. This AI-based ECG analysis tool is best suited for integrating into existing cardiology workflows to flag at-risk individuals (65+ without prior AF) for earlier intervention and follow-up.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | LVivo IQS | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | As an integrated part of an ultrasound and information technology (IT) system. | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
LVivo IQSLVivo IQS (Tool A) offers real-time image quality feedback directly during ultrasound scanning, which provides immediate, interactive guidance to users. This direct assistance at the point of care can significantly enhance the efficiency and quality of image acquisition. Tempus ECG-AF (Tool B) integrates for post-acquisition analysis, which is valuable but less interactive during the data capture phase.
Clinical Value
Tempus ECG-AFTempus ECG-AF (Tool B) provides a predictive risk assessment for new-onset Atrial Fibrillation within 12 months for a specific patient population, enabling proactive intervention and earlier follow-up for a serious condition. This predictive capability offers a distinct, forward-looking clinical advantage. LVivo IQS (Tool A) enhances the accuracy and efficiency of existing diagnostic ultrasound analysis, which is valuable but more focused on improving current workflows.
Pricing & Value
Tempus ECG-AFTempus ECG-AF (Tool B) explicitly details CMS reimbursement availability with specific CPT codes and a Medicare rate, providing clear economic transparency and a tangible value proposition for healthcare providers. LVivo IQS (Tool A) only states 'contact for pricing,' which offers less clarity on its economic value.
Enterprise Readiness
LVivo IQSBoth tools are FDA-cleared, HIPAA compliant, and offer BAAs, demonstrating strong foundational readiness. However, LVivo IQS (Tool A) is described as a 'vendor-neutral software solution' and deploys on ultrasound devices and PACS systems, suggesting broader and potentially easier integration across diverse existing IT infrastructures. Tempus ECG-AF (Tool B) specifies compatibility with major ECG vendors, which is good, but less universally applicable than 'vendor-neutral'.
Innovation
Tempus ECG-AFTempus ECG-AF (Tool B) utilizes AI for predictive analytics, identifying patients at risk of developing Atrial Fibrillation in the future based on ECG data, representing a significant advancement in proactive patient management. LVivo IQS (Tool A) applies AI to automate and enhance existing ultrasound image analysis, including real-time quality feedback, which is innovative but primarily improves current diagnostic processes rather than predicting future events.
Support & Docs
Tempus ECG-AFTempus ECG-AF (Tool B) explicitly provides contact information for a dedicated cardiology support team (email and phone) and mentions a 'Document Library' with technical information. While DiA Imaging Analysis (Tool A) provides product and regulatory details, explicit support channels or a comprehensive documentation portal are not as clearly highlighted in the available information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | LVivo IQS | Tempus ECG-AF |
|---|---|---|
| Name | LVivo IQS | Tempus ECG-AF |
| Company | DiA Imaging Analysis | Tempus AI, Inc. |
| Primary Use Case | Automate and enhance ultrasound image analysis for improved diagnostic confidence and efficiency in cardiology and other fields. | Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Target Specialties | Cardiology, Emergency Medicine, Radiology | Cardiology, Geriatrics, Internal Medicine |
| Specific Modality/Input | Ultrasound images | 12-lead ECG recordings |
| Target Patient Population | Not specified | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| Key Output/Detection | AI-powered real-time image quality feedback, automated analysis of ultrasound images, global and segmental left ventricle (LV) function evaluation, right ventricular (RV) function evaluation, bladder volume measurement. | Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months. |
Videos
Demos, reviews, and walkthroughs featuring LVivo IQS and Tempus ECG-AF.
Frequently Asked Questions
More Comparisons
More matchups featuring LVivo IQS or Tempus ECG-AF
Backers
Who funded each tool's parent company.